March 2013
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
ETHAN Trial: Rethinking Endocrine Therapy for Men's Breast Cancer
3
Contrasting Myeloma Therapies for Late Relapse in Patient Declining CAR T
4
Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer
5
